Postdoctoral Researcher – Genomics, Proteomics, and Clinical Outcomes at Eli Lilly and Company

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

PhD in statistical genetics, bioinformatics, computational biology, biostatistics, or a related quantitative field
Expertise in whole genome and whole exome sequencing analysis, proteomics, metabolomics and other molecular data analysis, and clinical outcomes research (preferred)
Strong proficiency in statistical modeling, machine learning, and high-dimensional data analysis (preferred)
Experience working with large biobank and cohort datasets (e.g., UK Biobank, All of Us, FinnGen) (preferred)
Proficiency in programming languages such as R, Python, and SQL for data analysis (preferred)
Familiarity with genetic association studies, GWAS, and polygenic risk scores (preferred)
Excellent communication and collaboration skills to work effectively in cross-functional teams (preferred)
Experience in pharmaceutical or biotech industry settings (preferred)
Knowledge of functional genomics and multi-omics data integration (preferred)
Strong publication record demonstrating contributions to statistical genetics and biomarker discovery and analysis (preferred)

Responsibilities

Apply statistical and computational approaches to analyze WGS/WES, proteomics, metabolomics, and clinical data for biomarker discovery
Conduct rigorous analyses of large-scale population cohorts and biobank datasets to identify genetic variants and causal genes associated with disease outcomes
Develop and implement machine learning and bioinformatics pipelines to integrate multi-omics data
Collaborate with interdisciplinary teams, including geneticists, epidemiologists, and clinicians, to interpret findings and guide therapeutic development
Prepare scientific reports, presentations, and publications detailing research outcomes
Contribute to the development of novel statistical methods for analyzing high-dimensional biological data
Support the data, tools and infrastructure that are critical for enabling research and development objectives
Integrate and analyze genomic, proteomic, metabolomic and phenotypic data from publicly available biobank and proprietary data sets on cloud based clinical multi-omics platforms

Skills

Genomics

Proteomics

Whole Genome Sequencing

WGS

Statistical Genetics

Bioinformatics

Multi-omics

Cloud Platforms

Data Integration

Biobank Analysis

Clinical Outcomes

Metabolomics

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free